The respirator is 11,000,000 times more efficient in filtering Influenza A viruses than N95
JEFFERSON, N.C., Aug. 5, 2009 — Next Safety, Inc. (NSI) announces advanced respirators that give people more confidence to go to work in a pandemic environment. Next Safety is releasing for sale to the public respirator products the company developed for the bird flu influenza A subtype H5N1.
The respirators were originally developed for the bird flu (H5N1), which never became contagious. The Next Safety respirators are now being sold to the public for the first time. These respirators are a cross functional platform that supply highly purified air to half facemasks and air supply hoods.
Next Safety designed its respirators with input from the CDC and the World Health Organization along from the US army’s famed AMRIID bioterrorism warfare center.
Next Safety’s core competence is the development, design and rapid production of pulmonary products like its 9000 series respirators. Next Safety respirators are rated for 30,000 hours of continuous operation.
Next Safety respirator products are fabricated from battlefield-grade medical plastics. Next Safety uses compound filters that do not fail. Texas Instruments and EBM-Pabst power Next Safety’s respirator products.
As with all respirator products, to be effective, Next Safety respirators must be used with proper eye protection and with a well-defined and understood decontamination program.
Next Safety is a leader in the development of pulmonary health products. It has a product line of advanced respirators that were developed for many different applications.
The company also develops pulmonary drug delivery products. It is a leader in the development of nicotine delivery devices for smoking cessation and nicotine replacement products.
Next Safety has 28 US patents that are either issued are pending for its products.
Next Safety is also developing other pulmonary drug delivery platforms for inhaled antibiotics and anti-medics, concentrated narcotics and drugs to treat pulmonary conditions such as asthma, COPD and the immune compromised.
The doctors, scientists and engineers who work for Next Safety have developed the most comprehensive and effective solution for the pulmonary delivery of medicines to in-home patients and persons who are addicted to smoking cigarettes. The company is developing combined respirator and pulmonary drug delivery systems for soldiers to have highly sophisticated medical care that greatly enhances their likely hood of survival in battle.
Next Safety engineers are experts in high-volume manufacturing. The company’s engineers and managers have made more than 40 million electrical devices a month for years. These are products that are designed to protect babies and children.
Next Safety has invested in significant capacity for pandemic stockpiling. The company expects to build approximately 5 million respirators for delivery in December 2009 and has the capacity to build 300 million respirators a month for pandemic stockpiling by March 2010.
Next Safety thanks the doctors and staff at Italy’s level-4 Milan biological research center for helping it design the best respirators for pandemic stockpiling.
Next Safety’s advanced respirator product line is available at .
Contact:
Eric Hunter
336-246-7700
# # #
